"Psychedelics, Rebirth Experiences, and the Limits of Current Research" www.sciencedirect.com/science/arti... I wonder what feelings or "body memories" this piece will elicit among researchers concerned with memory-related psychedelic phenomena... @manojdoss.bsky.social @kangaslampi.bsky.social

Good to see this important commentary with @kangaslampi.bsky.social, @rzeifman.bsky.social and @moeswisdom.bsky.social published in Psychedelic Medicine! Strongly appreciate the journal's commitment to healthy scientific discourse.

I'm talking with a patient from the Otsuka/Transcend methylone phase-II trial. They said there it essentially included therapy. The drug was presented as something that would help them process emotions/memories, like MDMA does. They planned to address certain emotions/memories before each session.

I probably spent 10,000 words in my upcoming book trying to say what these few paragraphs sum up way more succinctly. Happiness in a pill, sold to you at a reasonable profit-making price. That's the goal here. Stay home. Shut up. Be content. Fight our wars. Pay your bills. Take your happy pill.

Strong alliance, weak conclusions: Comment on Goodwin et al. (2026) “The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression” osf.io/preprints/ps... Many thanks to my coauthors Rick Zeifman, @kangaslampi.bsky.social & @moeswisdom.bsky.social

Wow! Science! This is incredible. Not so much the findings which i only understand bits and pieces of, but the sheer scale of this project. This is why I got into science, the chance of someday contributing to our common goal of understanding the world we live in. www.science.org/doi/10.1126/...

Lifelong behavioral screen reveals an architecture of vertebrate aging

Mapping behavior of individual vertebrate animals across lifespan could provide an unprecedented view into the lifelong process of aging. We created a platform for high-resolution continuous behaviora...

science.org

Are Psychedelic Experiences Just Brain Activity? Bill reflects on a debate between Guy Goodwin and Max Wolff @trpwolff.bsky.social where it was suggested what people say about their experiences may be a kind of smokescreen and that the real explanation lies only in what is happening in the brain.

As a way of being a bit more active on here, I'll try to post some papers I have read each week + plus some opinions. So let's start with February 9th-15th:

Berlin: 28.1. Trip auf Rezept? Zur Zukunft Psychedelika-assistierter Therapie. Öffentliche Veranstaltung unseres Forschungsprojekts PSYCHEDELSI zu allerlei, auch nicht-medizinischen Themen. psychedelsi.org 18 Uhr, Medizinhistorisches Museum der Charité. Come along!

Lest we forget the Satanic Panic.

Samuli Kangaslampi@kangaslampi.bsky.social · 8mo ago

Critical commentary on a recent paper reporting emergence of dissociated traumatic memories during psilocybin treatment now out in the Journal of Eating Disorders, with @trpwolff.bsky.social, @manojdoss.bsky.social, Lilian Kloft-Heller, and @henryotgaar.bsky.social. doi.org/10.1186/s403...

Critical commentary on a recent paper reporting emergence of dissociated traumatic memories during psilocybin treatment now out in the Journal of Eating Disorders, with @trpwolff.bsky.social, @manojdoss.bsky.social, Lilian Kloft-Heller, and @henryotgaar.bsky.social. doi.org/10.1186/s403...

Questioning the recovery of dissociated traumatic memories under psilocybin: comment on “Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosa” - Journal of Eating Disorders

In their recent case report article, Peck and colleagues suggested that two patients recovered dissociated traumatic memories during psilocybin treatment for anorexia nervosa. These case reports are of clinical and scientific interest and confirm that psychedelics may induce vivid memory-like experiences. However, the reports warrant scrutiny. Here, based on what is known about recovered memories and the effects of psychedelics, we argue that the authors may not have adequately considered alternative explanations. The cases do not necessarily demonstrate that psilocybin induces recovery of dissociated traumatic memories or could treat dissociative amnesia. We further caution against the authors’ suggestion of explicitly preparing patients for the emergence of forgotten material.

doi.org

A review covering our clinical experiences working with people experiencing peristent challenges after using psychedelics and the research literature. Might be of interest @philosojules.bsky.social @trpwolff.bsky.social @trpr-ucsf.bsky.social www.psykologtidsskriftet.no/artikkel/202...

In this new commentary, @kangaslampi.bsky.social and I argue against viewing the psychedelic experience as a "biomarker" and challenge reductionistic drug-centered framings that obscure key psychosocial determinants of psychedelic therapy outcome, most notably psychotherapeutic processes. LINK ⬇️

Is the psychedelic experience a pharmacodynamic biomarker? Or do psychotherapeutic processes matter? Comment with @trpwolff.bsky.social on the recent Goodwin et al. (2025) paper now available online in the Journal of Affective Disorders: www.sciencedirect.com/science/arti...

Pharmacodynamic biomarker or psychotherapeutic process? Comment on “the role of the psychedelic experience in psilocybin treatment for treatment-resistant depression”

sciencedirect.com

Postdoctoral Fellowship Opportunity We are looking for excellent MD Psychiatrist applicants to work & train at the CPCR at Johns Hopkins @jhpsychedelics.bsky.social, the largest and most comprehensive psychedelic research program in the world. Email Dr. Sandeep Nayak smn@jhmi.edu

Finally got around to reading this great paper. A really insightful argument for treating psychedelic-assisted therapy as psychotherapy!

Max Wolff@trpwolff.bsky.social · 10mo ago

New long-read theory paper in Psychological Review: Im short, we propose that effective psychedelic therapy employs the uniquely context-dependent effects of psychedelic drugs to engage & augment the same psychological change processes that underlie all effective psychotherapies. Full text below ⬇️

To those who dismiss psychodynamic therapy, and perhaps especially to those who dismiss anything except psychodynamic therapy, this article comes highly recommended: psycnet.apa.org/doiLanding?d...

I've been saying that since I was 18, as I exited a Jimi Hendrix concert in Kansas City

New long-read theory paper in Psychological Review: Im short, we propose that effective psychedelic therapy employs the uniquely context-dependent effects of psychedelic drugs to engage & augment the same psychological change processes that underlie all effective psychotherapies. Full text below ⬇️

Classical randomized controlled trials (RCTs) can't capture the complexity of psychedelic therapy. In this new paper led by @sdmuthu.bsky.social and @tehseennoorani.bsky.social, we argue for pragmatic trials designs that accommodate this complexity and better align with real-world clinical practice.

New paper out with @tehseennoorani.bsky.social @maxwolff.bsky.social and orhers, showing that the UK Medical Research Council's framework for complex interventions offer an important way foward for the field of #psychedelics: journals.sagepub.com/doi/epub/10....

Has the time come to stop using "control groups" in trials of psychological interventions? — asks Pim Cuijpers. This discussion concerns psychedelic therapy, which is a (pharmacologically catalyzed) psychological intervention, just as well as any other form of psychotherapy. Link below.

From our recent article "Key competencies for psychedelic treatment in real-world mental health care settings" Full-text link below.

Recovering memories under MDMA or psychedelics and the impact of The Tell, a few scattered thoughts and observations: kangaslampi.net/the-tell-and...

Our new paper "Key competencies for psychedelic treatment in real-world mental health care settings" has just been published in General Hospital Psychiatry. Full-text link below.

My article "Experiments in medicalization" on the Swiss and Australian efforts to enable psychedelic therapies outside of clinical trials but short of market approval has just come out in BioSocieties: www.nicolaslanglitz.de/ewExternalFi...

Bluesky now platform of choice for science community - except for the psychedelic science community, which seems to have chosen Linkedin. What does this say about psychedelic science?

David Shiffman, Ph.D. 🦈@whysharksmatter.bsky.social · 11mo ago

Bluesky now platform of choice for science community - Ars Technica | Media coverage of our new paper

BREAKING: German regulators have green-lit the EU's first psilocybin compassionate access program. Unlike other countries’ pre-approval pathways, Germany’s does not require case-by-case regulatory approval and may see insurers cover costs. Details: psychedelicalpha.com/news/germany...

Germany Establishes EU’s First Psilocybin Compassionate Access Program - Psychedelic Alpha

Germany has become the first EU country to allow legal access to psilocybin under a compassionate use program for treatment-resistant depression. Unlike other countries’ pre-approval pathways, Germany...

psychedelicalpha.com

Our recent article "Reframing psychedelic regulation: Tools, not treatments" is discussed on the SPACE blog (in Portuguese): space.com.pt/blogue/regul...

Regulamentar Psicadélicos como Ferramentas, Não como Tratamentos | SPACE Portugal — Sociedade Portuguesa de Aplicação Clínica de Enteógenos

O artigo de Wolff et al. (2025), "Reframing psychedelic regulation: Tools, not treatments", constitui uma contribuição oportuna e...

space.com.pt